Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Eisai Inc.
NeoImmuneTech
Eli Lilly and Company
Essen Biotech
Essen Biotech
AstraZeneca
Stemline Therapeutics, Inc.
DualityBio Inc.
M.D. Anderson Cancer Center
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
Eli Lilly and Company
Eli Lilly and Company
National University Hospital, Singapore
A2 Biotherapeutics Inc.
Palleon Pharmaceuticals, Inc.
NuCana plc
Bristol-Myers Squibb
Numab Therapeutics AG
AtlasMedx, Incorporated
Lantern Pharma Inc.
Intensity Therapeutics, Inc.
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Cyteir Therapeutics, Inc.
Aminex Therapeutics, Inc.
Simcha IL-18, Inc.
Daiichi Sankyo
Salubris Biotherapeutics Inc
Cantargia AB
Cancer Research UK
CytomX Therapeutics
NBE-Therapeutics AG
Kineta Inc.
Tesaro, Inc.
Kiadis Pharma
NKGen Biotech, Inc.
University of California, San Francisco
Lumos Pharma
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Puma Biotechnology, Inc.
East and North Hertfordshire NHS Trust
Sanofi
AstraZeneca
Hanmi Pharmaceutical Company Limited
BBB-Therapeutics B.V.
AlphaVax, Inc.
University of Plymouth